Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
BMC Health Services Research|May 5, 2026
Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in ItalyCarla Rognoni, Giacomo Loseto, Antonio Cuneo, et al.
Leukemia & Lymphoma|December 5, 2008
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemiaMassimo Breccia, Caterina Stefanizzi, Laura Cannella, et al.
Critical Reviews in Oncology/Hematology|June 16, 2024
Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitorsFrancesca R Mauro, Anna Maria Frustaci, Andrea Visentin, et al.
Blood Reviews|February 8, 2024
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelinesMalgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, et al.
Leukemia & Lymphoma|September 2, 2024
Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemiaMarina Deodato, Anna Maria Frustaci, Arianna Zappaterra, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2009
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?Massimo Breccia, Anna Maria Frustaci, Laura Cannella, et al.
Hematological Oncology|January 21, 2023
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experienceLuca Laurenti, Lydia Scarfò, Anna Maria Frustaci, et al.
Hematological Oncology|March 11, 2009
Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patientsMassimo Breccia, Anna Maria Frustaci, Laura Cannella, et al.
Cancers|April 30, 2021
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma CellsAlessandra Trojani, Barbara Di Camillo, Luca Emanuele Bossi, et al.
Haematologica|November 22, 2011
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceCorrado Girmenia, Anna Maria Frustaci, Giuseppe Gentile, et al.
Pageof 5